John Rountree, Managing Partner of Novasecta, was recently quoted in the Sunday Times, the UK’s leading Sunday newspaper. In an article entitled “How to Make Our Scientists Very Mad” John offers commentary on the risks of Brexit to early-stage biotech companies, stating that the potential for decreased funding (from Horizon 2020, for example) may reduce the attractiveness of life sciences “hubs” such as London, Cambridge and Oxford. The article goes on to say that diminished research output of academia and biotechs from these hubs, combined with the likely relocation of the European Medicines Agency (EMA), may delay new medicines reaching British patients by two to three years.
What our clients
say about us
We have worked collaboratively with Novasecta over many years across a range of strategic topics. I have particularly valued how they really understand and care about our business, and how they manage to apply their deep industry insights to our context. This has brought my Management Team and Board to clarity and alignment on practical strategic moves at important moments in our evolution as a company.CEO – Biotech